Table 4.

Treatment response and survival of patients carrying EGFR mutations.

Patient	EGFR Alteration	Therapy	Response to Therapy Protocol	Status	Survival (Months)
P3	p.L861Q	Chemotherapy	Good response to chemotherapy then metastasis	died	37
P27	p.L861Q	Chemotherapy + Erlotinib	Complete remission	alive	40
P34	p.L861R	Chemotherapy	Bad response to chemotherapy	died	18
P36	p.E746_A750del/p.L861R	Erlotinib	63% tumor regression then resumption of tumor progression	alive	15
P37	p.G719S	Chemotherapy	Bad response to chemotherapy	died	35
P42	p.E746_A750del	Chemotherapy	Good response to chemotherapy	alive	17
P136	p.E746_A750del	Surgery	No treatment	alive	7
P139	p. G719C	Chemotherapy	Good response to chemotherapy	alive	18
P140	p. L861Q	Chemotherapy + Erlotinib	Chemotherapy then 2 weeks of erlotinib, died of interstitial lung disease	died	1
P149	p. L861R	Erlotinib	Treated for 1 month	alive	3
P157	p. L861Q	Erlotinib	Treated for 2 months	alive	2
P160	p. L858R	Erlotinib	Treated for 1 month and 2 weeks	alive	2